CHA
VRDN icon

Carmichael Hill & Associates’s Viridian Therapeutics VRDN Stock Holding History

Carmichael Hill & Associates’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$910 Hold
40
– – ﹤0.01% 738
2024
Q2 		$521 Hold
40
– – ﹤0.01% 747
2024
Q1 		$701 Hold
40
– – ﹤0.01% 733
2023
Q4 		$872 Hold
40
– – ﹤0.01% 747
2023
Q3 		$614 Hold
40
– – ﹤0.01% 751
2023
Q2 		$952 Hold
40
– – ﹤0.01% 737
2023
Q1 		$1.02K Hold
40
– – ﹤0.01% 727
2022
Q4 		$1.17K Hold
40
– – ﹤0.01% 709
2022
Q3 		$1K Hold
40
– – ﹤0.01% 797
2022
Q2 		$0 Buy
+40
New +$538 ﹤0.01% 875

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Carmichael Hill & Associates's VRDN Position: Q3 2024 in Review

Carmichael Hill & Associates held its Viridian Therapeutics (VRDN) position steady in Q3 2024 at 40 shares worth $910. The position accounts for ﹤0.01% of the portfolio, ranked #738.

Carmichael Hill & Associates first reported a position in VRDN in Q2 2022 and has held it in 10 quarters since. The position peaked at $1.17K in Q4 2022. 165 funds tracked by Wall St. Rank hold VRDN as of Q3 2024.

  • Carmichael Hill & Associates held 40 shares of Viridian Therapeutics worth $910 as of Q3 2024.
  • Carmichael Hill & Associates left its Viridian Therapeutics share count unchanged in Q3 2024.
  • Viridian Therapeutics made up ﹤0.01% of Carmichael Hill & Associates's portfolio in Q3 2024, its #738 holding.
  • Carmichael Hill & Associates first reported a position in Viridian Therapeutics in Q2 2022 and has held it in 10 quarters since.
  • Carmichael Hill & Associates's Viridian Therapeutics position peaked at $1.17K in Q4 2022.
  • 165 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2024.

Based on Carmichael Hill & Associates's 13F filing for Q3 2024, filed 29 Oct 2024.